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List of frequently used abbreviations: 
ROS, reactive oxygen species
RNS, reactive nitrogen species
NADH, nicotinamide adenine dinucleotide (reduced)
O2
•-, superoxide anion radical
NO•, nitric oxide radical
GSH, glutathione (reduced)
ETC, electron transport chain
DYm, mitochondrial transmembrane potential
IMM, inner mitochondrial membrane
OMM, outer mitochondrial membrane




Q, coenzyme Q10, ubiquinone, quinone
FADH2, flavin adenine dinucleotide (reduced)
mPTP, mitochondrial permeability transition pore
VDAC, voltage dependent anion channel
HKI and HKII, hexokinase I and II 
MnSOD, manganese superoxide dismutase
MnTBAP, Mn(II)tetrakis(4-benzoate) porphyrin chlorine
OXPHOS, oxidative phosphorylation
UCP, uncoupling proteins











L-NAME, NG-nitro-L-arginine methyl ester








MAPK, mitogen-activated protein kinase
Introduction
 Mitochondria are known for their essential role 
as energy transducers, but mitochondria also perform 
critical functions such as cell division and apoptosis 
(59). Mitochondria are effectors of both ischemia and 
reperfusion (I/R) injury and cytoprotection. Therapeu-
tic targeting of mitochondria has emerged recently as 
a subject of interest because of the plausible alterna-
tive approach this offers in our efforts to treat some dis-
eases. The implication or association of mitochondria 
in the etiology of many disease states, including heart 
disease, has heralded novel therapeutic approaches 
aimed to specifically target mitochondria. 
 Overall cellular function is dependent on O2 
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Abstract 
 The mitochondrion has evolved as an important organelle in 
determining cell survival and cell death. It is involved in a plethora of proc-
esses in mammalian cells including ATP production, steroid synthesis, and 
cell division and cell death. Indeed, mitochondrial dysfunction is associated 
with numerous human maladies including heart disease. Mitochondrial 
diseases have traditionally been attributed to defects in the electron trans-
port chain (ETC), the major source of mitochondrial reactive oxygen spe-
cies (ROS), a byproduct of mitochondrial respiration. Mitochondrial cation 
channels and exchangers function to maintain matrix homeostasis and are 
likely involved in modulating mitochondrial function in part by regulating 
O2
•- generation. Insofar as mitochondria are involved in oxidative dam-
age that leads to apoptosis, antioxidants and other therapeutic strategies 
that target the organelle appear to be a novel approach to alleviate some 
cardiovascular diseases. This novel approach has gained unprecedented 
attention recently with a significant potential for future therapeutic pur-
pose. Whether mitochondria are targets or end effectors of cardiac pre- and 
post-conditioning remain unresolved. This brief review will provide the lat-
est information gleaned from the literature on the role of mitochondria in 
pre- and post-conditioning during cardiac ischemia and reperfusion.
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consumption by functioning mitochondria to produce 
energy with minimal electron leak to generate the su-
peroxide (O2
•-) anion (15,71). Mitochondria are therefore 
vital for normal cellular function including intracellular 
metabolic activities and signal transduction of various 
cellular pathways during normal and abnormal states. 
Cell signaling pathways induced physiologically by 
reactive oxygen species (ROS) include effects on thiol 
groups and disulfide linkages, which post-translation-
ally modifies protein structure to activate/inactivate 
specific kinase/phosphatase pathways (15). Similarly, 
mitochondrial proteins can be targets of extra-matrix 
signaling molecules with concomitant changes in 
mitochondrial bioenergetics and cellular protection 
against oxidative stress. Mitochondrial constituents 
such as proteins, lipids, and mitochondrial DNA are 
themselves targets of oxidative/nitrosative stress, and 
the mitochondrial control of oxidative stress has con-
sequences both for cellular energy metabolism and for 
the processes that control the onset and progression 
of the cell death response (15). A protected electron 
transport chain (ETC) during pre- and post-condition-
ing is therefore critically important for the recovery of 
the post-ischemic heart.    
 An understanding of mitochondrial function in 
normal and pathological states is essential to amelio-
rate or prevent mitochondria related cardiac dysfunc-
tion, like I/R injury. Thus, the recent spotlight on mito-
chondria is attributed to its role in cell death, in which 
excess ROS (O2
•- and its products) and dysfunction in 
the energy production process are underlying factors. 
O2
•-, which is generated at several sites within the ETC 
and the matrix, is mostly converted to H2O2 both inside 
and outside the mitochondrial matrix by O2
•- dismutas-
es. H2O2 is a major, highly diffusible, chemical messen-
ger that, in low amounts, physiologically modulates 
cell function (15).  
 Diseases of the mitochondria appear to cause 
most damage to cells that are metabolically active, like 
the heart, brain, liver, kidneys and skeletal muscle. In 
a recent comprehensive review (15), we discussed sev-
eral mitochondrial related diseases, which will not be 
discussed here. The objective of this brief review is to 
provide the role of mitochondria in I/R injury and to 
note the potential therapeutic approaches to mitigate 
mitochondria-related dysfunction, specifically pre- and 
post-conditioning.
Overview of Mitochondrial Anatomy and Func-
tion: Implications for Ischemia and Reperfusion 
Injury and Cytoprotection 
 Mitochondria are the key cellular organelles 
charged with synthesizing ATP via oxidative phospho-
rylation (OXPHOS) (Figure 1). They have major roles in 
cellular physiology beyond ETC and OXPHOS. Mito-
chondria are also involved in intracellular Ca2+ home-
ostasis, ROS production, and apoptosis. Mitochondrial 
compartments include the outer and inner mitochon-
drial membrane (OMM and IMM, respectively) (Figure 
1), the inter-membrane space (IMS), and the matrix. The 
membranes and the IMS are intimately involved in con-
trol of cell function and cell death.
 The OMM plays an important role in controlling 
mitochondrial activity. The OMM and IMS limit the pas-
sage of proteins and small solutes that regulate many 
cellular processes and initiate or inhibit apoptotic 
pathways.  The OMM is a relatively simple phospholipid 
structure that contains many channel proteins. OMM 
permeabilization is considered the ‘point of no return’ 
as this event is responsible for initiating the apoptotic 
cascade in numerous cell death pathways (22). The re-
lease of, for example, cytochrome c triggers formation 
of an “apoptosome” that leads to activation of the ex-
ecutioner caspases (22). It is possible that under normal 
conditions changes in mitochondrial dynamics also 
modulate OMM permeabilization to induce apoptosis 
(17,18). 
 The most abundant protein on the OMM is the 
VDAC. It acts as a conduit for translocating ions and a 
variety of metabolites such as ATP and ADP across 
the OMM. As a major gateway in and out of the mito-
chondrion, VDAC mediates a delicate balance between 
metabolism and death in cells (15). However, follow-
ing I/R, a 4-fold increase in VDAC phosphorylation has 
been reported (66) and the cardioprotective effect of 
PD169316, an antagonist of p38 mitogen-activated 
protein kinase (MAPK) resulted in a significant reduc-
tion in ischemia-induced phosphorylation of VDAC, 
specifically a reduction of tyrosine phosphorylation 
(66).
 The VDAC is also a receptor for hexokinases 
(HK) and the VDAC-HK binding has been implicated 
in cell survival and cell death. HK II binding to VDAC is 
believed to maintain mitochondrial membrane integ-
rity and to prevent the Ca2+-dependent opening of 
the mitochondrial permeability transition pore (mPTP) 
(80). The mPTP is a mega-pore that connects IMM and 
OMM proteins with the result that mitochondrial per-
meability increases and cell demise ensues. Exposure 
to apoptotic stimuli causes a decline in mitochondrial 
HK II activity (31). In the heart, it has been suggested 
that the mitochondria-HK interaction may indeed be 
an integral part of cardioprotection, including ischemic 
and pharmacologic preconditioning (IPC and PPC, re-
spectively) (85).
 In addition to mCa2+, mPTP opening appears 
to be instigated by high levels of ROS, increased Pi and 
a high matrix pH (15). Since matrix pH likely becomes 
more acidic during ischemia, pore opening will not be 
favored. Therefore, matrix acidification during I/R has 
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been shown to be a beneficial strategy in attenuating 
I/R damage (15). In contrast, matrix alkalinization on 
reperfusion may induce pore activation, so continued 
acidification during reperfusion or inhibition of Na2+/
Ca2+-exchanger (NCE) to minimize cytosolic and mi-
tochondrial Ca2+ overload would be strategically ben-
eficial during this period to reduce cell death. Indeed, 
acidification has been shown to be effective in post-
conditioning protection as demonstrated by inhibited 
pore opening (15). 
 We and other investigators have also assessed 
myocardial mPTP opening in the intact heart, prior to 
the onset of contractile dysfunction during I/R, and in 
isolated mitochondria (2,10,33). We showed that I/R 
increases the vulnerability of isolated mitochondria 
to increased extra-matrix Ca2+ challenges (2). In the 
cardiac dystrophied mdx mouse model, evaluation 
of mPTP in the intact isolated heart model using the 
3H-DOG method showed increased mPTP opening as 
evidenced by release of cytochrome c when hearts un-
derwent I/R (10). Mitochondria from isolated hypertro-
phied rat hearts exhibited an increased susceptibility 
to opening of mPTP in response to physiological stres-
sors (i.e., Ca2+ overload and anoxia and reoxygenation) 
and H2O2 (10,15). 
 In the IMM, a large DYm (negative inside) is 
formed across the IMM by outward proton pumping 
by the respiratory enzymes of the ETC. The IMM charge 
separation and transmembrane cation fluxes via spe-
cialized cation channels/uniporters, symporters, and 
exchangers are essential for mitochondrial respiration 
and function (15). Activation of the exchangers allows 
extrusion of cations entering the matrix down their 
concentration gradient, thus preventing volume ex-
pansion. The IMM also contains the adenine nucleotide 
translocator (ANT), which is considered a crucial com-
ponent of the mPTP. The ANT has been shown to be a 
target for oxidative and nitrosative stress and therefore 
is an important component in I/R injury. In cardiac my-
ocytes, connexin 43 (Cx43), the predominant protein in 
gap junctions in ventricular myocardium, is also local-
ized in the IMM of cardiomyocyte mitochondria (15) 
and has been implicated recently as a factor in pre- and 
post-conditioning (65). 
 There is increasing evidence that mitochon-
dria, which have a large capacity to take up Ca2+, play 
a critical role in maintaining intracellular Ca2+ homeos-
tasis in I/R (15). During I/R, increased cytosolic Ca2+ may 
lead to mCa2+ overload via the mitochondrial Ca2+ uni-
porter (Figure 1), and in the presence of ROS, may lead 
to mPTP opening and cell death. Therefore, preventing 
Ca2+ uptake at times of increased cytosolic Ca2+ due to 
oxidative stress has proven to be a viable strategy to 
mitigate cellular damage during I/R. In a recent study it 
was reported that melatonin, a pineal gland hormone 
protect against brain I/R injury in part by preventing 
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Figure 1: Figure shows basic structural components of the ETC complexes as well as the sites of proton pumping during 
electron transport that leads to the generation of ATP. NADH and FADH2 (from Krebs cycle) needed to energize mitochondria 
and establish the mitochondrial membrane potential (ΔYm; -180 to -200 mV). The ΔYm can be modulated be uncoupling 
proteins (UCP). Phosphates are imported and exported through the adenine nucleotide translocase (ANT). Substrate uptake 
is mediated through mitochondrial inner membrane (IMM) proteins [e.g., carnitine palmitoyl transferase (CPT) and pyruvate 
dehydrogenase (PDH). Ca2+, which may modulate mitochondrial respiration, is taken up via the calcium uniporter (CaU).  
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mCa2+ mediated apoptosis (35).   
 In mitochondria K+ flux also plays a significant 
role in normal mitochondrial function and cytopro-
tection against apoptosis. The putative mitochondrial 
KATP (mKATP) and the mitochondrial KCa (mKCa) channels 
are involved in protection against I/R injury. The mKATP 
channel agonist diazoxide has been shown to protect 
cells from I/R damage in part by minimizing mCa2+ up-
take through depolarization of DYm (28,53). A prototype 
of mKATP channel opener, BMS-180448, has cardiopro-
tective effects and is currently in clinical trials (58). We 
recently provided evidence for a regulatory role of the 
putative mKCa channel opening on matrix pH and vol-
ume (4). We also showed that pre-ischemic exposure to 
the big KCa channel agonist, NS1619 provided protec-
tion against I/R injury by reducing mitochondria-medi-
ated ischemia-induced ROS production (70). However, 
the role of mitochondrial K+ channels in cell protection 
remains uncertain because the molecular structure of 
these channels has not been identified.
 The IMM also contains the ETC complexes that 
furnish the structures for proton translocation, and in 
the process function to convey electrons down the ETC 
along an energy gradient (15,41,71). Electrons pass from 
NADH and FADH2 via complexes I and II, respectively, to 
downstream complexes (Fig 1). Translocation of proton 
along the electrochemical gradient from the IMS to the 
matrix through complex V (F1/F0 ATPsynthase) drives 
phosphorylation of ADP to ATP (15,71) and transiently 
dissipates the DYm. In the process of electron transport, 
electrons can leak resulting in O2
•- generation. The leak 
is more severe during I/R and hence the combining of 
O2 and free electrons contributes to the pathology of 
mitochondria.
 We and other investigators have shown that 
targeting the ETC complexes for therapeutic purpose 
is in part attributed to the vulnerability of mitochon-
dria to oxidative stress. We observed and reported that 
the partial complex I blocker amobarbital protected 
against I/R injury when the drug was perfused briefly 
only just before ischemia; we concluded from this study 
that the protection was mediated by limiting electron 
flow from upstream to complex III, a major source of 
ROS (3,15). These observations are consistent with 
studies that show rotenone, a complex I blocker given 
on reperfusion, did not provide as much protection in 
preserving the integrity of mitochondrial structure and 
function, as when the drug was administered before 
ischemia (20). Therefore, maintaining the structural 
and functional integrity of mitochondrial complexes 
and associated structures is a prerequisite for normal 
cell function. Furthermore, these studies highlight an 
emerging paradigm that reversible metabolic inhibi-
tion may be a common pathway leading to cellular 
protection and that the ETC regulates apoptosis (15). 
 The uncoupling proteins (UCPs) are IMM 
transporters that control the rate of electron transfer 
through the ETC (62). Mitochondrial uncoupling is an 
important physiological regulator of mitochondrial 
function because of its effect on redox potential and 
O2
• production (15). A small class of “uncoupling” pro-
teins called UCPs 1-4 and fatty acids are believed to in-
duce an inward proton “leak” in charged mitochondria 
(15,71). Uncoupling agents have shown promise as po-
tential mediators of cytoprotection by minimizing the 
levels of cytotoxic ROS. For instance, activation of the 
putative mKATP channels may lead to mild uncoupling 
of mitochondrial respiration via mild “proton leak” with 
a concomitant increase in O2
•− generation that provides 
the signal for protection against ischemic damage (15); 
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Figure 2: Principal mechanisms for mitochondrial ROS and 
RNS generation. Reduced substrates synthesized in meta-
bolic pathways supply electrons (e-) to ETC complexes. The 
major centers for O2
•- formation are complexes I and III. The 
electron carrier of complex III ubiquinone (Q) is reduced to 
ubiquinol (QH2), which transfers an electron to cytochrome c 
(Cy C) through an Fe protein (not shown) inhibited by myxo-
thiazol (Myx). The resulting semiubiquinone (Q•) is oxidized 
back to ubiquinone by cytochrome b (Cy b), and can also 
transfer e- to O2 to form O2
•-. Myxothiazol reduces O2
•- pro-
duction because it blocks Q• formation, whereas antimycin A 
(Ant A) enhances it by increasing Q• levels. The drug rotenone 
(Rot) inhibits complex I to generate some O2
•-. The O2
•- gener-
ated by Myx are directed to the matrix where they are scav-
enged; O2
•- generated by Ant A are released into the IMS and 
so escape the powerful matrix scavengers. The figure also 
depicts the dismutation of O2
•- and its reaction with NO• to 
form ONOO-. Reproduced with permission Camello-Almaraz 
et al (16). SOD, superoxide dismutase; H2O2, hydrogen perox-
ide; ONOO-, peroxynitrite; NO•, nitric oxide; DYm: mitochon-
drial potential; AS, ATPsynthase; OMM, outer mitochondrial 
membrane; IMM, inner mitochondrial membrane; IMS inter-
membrane space, CAT catalase, reduced GSH glutathione, 
oxidize glutathione GSSG.
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DYm may be a mechanism of anesthetic precondition-
ing (APC) (67). These interesting findings could provide 
new insight as to the mechanisms by which anesthetic 
preconditioning confers protection against I/R injury.   
Mitochondrial Reactive Oxygen and Nitrogen 
Species: Role in Cell Survival and Injury 
 Reactive oxygen species, including superoxide 
anions (O2
•-) hydrogen peroxide (H2O2), and ferryl hy-
droxyl radicals (FeOH•) are continuous byproducts of 
normal mitochondrial aerobic metabolism (Figure 2) 
that can oxidize nucleic acids, lipids and proteins, and 
in other cases nitrosylate proteins leading to the modi-
fication and/or loss of functions. Under normal condi-
tions, potentially toxic ROS generated by mitochondria 
ETC are efficiently detoxified by mitochondrial and cy-
tosolic scavenging systems. However this balance can 
be upset and lead to excess ROS and reactive nitrogen 
species (RNS), like nitric oxide (NO•) and peroxynitrite 
(ONOO-) (15). Therefore, the balance between ROS and 
RNS generation and their detoxification is a critical de-
terminant of cell survival and cell death. To maintain 
this delicate balance mitochondria are equipped with 
endogenous antioxidant defenses that regulate O2
•− 
within a physiological range (Figure 2).
 Physiological levels of ROS are important in 
that they are key part of cell signaling molecules for 
normal cell function as well as in cytoprotection during 
pre- and post-conditioning. Under pathological condi-
tions, the delicate balance (generation – scavenging) 
that keeps the level of O2
•− to a minimum is altered 
so that the rate of O2
•− generation exceeds the rate of 
scavenging. By maintaining the level of antioxidants in 
the matrix and by minimizing electron flow to complex 
III, we may have a potential therapeutic approach to 
neutralize oxidative-stress-induced mitochondrial dys-
function and subsequent apoptosis.  
 Tissue damage during disease processes has 
long been known to be associated with increased lev-
els of ROS. Increased mitochondrial ROS production, 
for example during cardiac I/R injury, can impair com-
plex I (46), which in turn can enhance O2
•− formation as 
a result of increased electron leak as electron transfer is 
impeded (15). Studies have shown that an increase in 
H2O2 generation in mitochondria isolated after cardiac 
I/R injury was enhanced by either rotenone or antimy-
cin A; this suggested that both complexes I (Q and/or 
N2 (final) Fe-S center) and III were damaged and capa-
ble of producing O2
•- after I/R injury (Figure 2) (15,71).
 In addition to induction of ROS by hypoxia, 
ischemia, and mitochondrial toxins/drugs, ROS per 
se may lead to even greater ROS generation in a self-
amplifying manner. This phenomenon, called ROS-
induced ROS release, may be associated with mCa2+ 
overload and may play a role in initiating apoptosis; 
but whether normal stimuli initiate it is not known (71). 
It seems unlikely that Ca2+ overload can itself induce 
ROS generation because it dissipates DYm and lowers 
the redox state (16); but it may hinder the ROS scav-
enger system so that more ROS is produced (15,71). In 
our studies though, during early ischemia in isolated 
hearts, ROS increased along with mCa2+ and redox state 
(NADH) (3,5,13) and treatment with exogenous ROS 
scavengers reduced ROS and mCa2+ and better main-
tained redox state (NADH) during I/R injury (13,70). 
 The RNS NO• and its derivatives are mediators 
of numerous vital physiological processes including cy-
toprotection; they are also mediators of cell injury (69). 
NO• binds to the O2 binding site of complex IV, block-
ing energy production in the same way as hypoxia. This 
may be one way in which cells regulate their energy 
production. It may also be one way in which our body 
kills pathogens. Physiologically, NO• has four major ef-
fects on mitochondria: 1) inhibition of complex IV, 2) 
inhibition of complex I, 3) indirect stimulation of mito-
chondrial biogenesis, and 4) pathologically full activa-
tion of mPTP. These actions of NO• can be direct, such as 
binding to complex IV or mPTP activation, or through 
NO• derivatives. NO• generates ONOO- when it reacts 
with mitochondrial O2
•-; ONOO- at high concentrations 
activates opening of the mPTP. Other NO• based prod-
ucts, such as S-nitrosothiols (SNO), inhibits complex I, 
which in turn can increase O2
•- and H2O2. SNO can also 
activate mPTP opening (15). 
 At low concentrations NO• provides cytopro-
tection from oxidative stress induced by I/R injury or 
hypoxia with reoxygenation. Inhibition of complex IV 
by NO• is thought to elicit cardioprotection by protect-
ing the limited supply of O2. Other experimental evi-
dence to date supports the cytoprotective effect of NO• 
binding to complex IV as shown by resistance to apop-
tosis (24). NO• is strongly implicated in the mechanisms 
underlying cytoprotection mediated by ischemic pre-
conditioning (IPC) in part by its inhibition of complex 
I (15,24). SNO inactivation of complex I results in inhi-
bition of respiration and causes a small increase in O2
•- 
and H2O2 generation. It is thought that the generation 
of ROS may be one of the signaling mediators of pre-
conditioning (40,72). 
Potential Therapeutic Implications for Mitochon-
drial ROS Scavenging 
 ROS and RNS are clearly involved in normal 
cellular functions, cellular injury, and cytoprotection. 
In a recent review (15) we asked could “modulation of 
ROS/RNS be an effective therapeutic tool?” To address 
this question the need to efficiently neutralize patho-
logic ROS and RNS has to be balanced with the need 
to maintain these species at physiological levels. The 
mitochondria and the cell are both equipped with an 
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armament of radical scavengers. These include the in-
tra- and extra-matrix SODs, and glutathione (GSH) (71) 
systems, catalase (cytosolic and possibly mitochondri-
al) GSH peroxidase and cytochrome c (15,71). Detailed 
review of ROS scavengers, which is beyond the scope 
of this review, has been discussed in our recent com-
prehensive review articles by the authors (15,71).
 MnSOD (SOD2) is located primarily in the mi-
tochondrial matrix. It is only known role is to detoxify 
O2
•- to H2O2, thereby protecting the mitochondrial Fe-S 
cluster containing enzymes from oxidative damage 
(15). Mitochondrial SOD mimetics (non-protein) have 
been developed to allow uptake into the mitochondri-
on to scavenge ROS. This includes, the synthetic metal-
loporphyrins, manganese (III) tetrakis  (4-benzoic acid) 
porphyrin (MnTBAP). Unlike enzymatic exogenous 
SODs the metalloporphyrins are highly permeable (15). 
 We reported that MnTBAP alone abolished car-
dioprotection by mKCa channel opening (70) and IPC 
(37), suggesting the importance of ROS in the mech-
anism of cytoprotection in these studies. The metal-
loporphyrins have also gained attention recently in 
organ and tissue transplant. Studies have shown that 
oxidative stress resulting from I/R can cause endothe-
lial dysfunction in the vein graft with the possibility 
of graft failure. The addition of MnTBAP during coro-
nary and lower limb arterial reconstruction improved 
endothelium-dependent vasorelaxation in harvested 
saphenous vein (68). Attempts to incorporate these 
therapies in the realm of human organ transplantation, 
however, remain unresolved. One would hope in time 
that with increased oxidative stress due to reduction in 
endogenous scavengers in allografts (64), the potential 
beneficial role of synthetic MnSOD mimetics would be-
come clinically applicable.
 Glutathione is a tri-peptide with the thiol (-SH) 
residue of cysteine as its active site; it is regulated by 
the cytosolic redox state. It provides protection for mi-
tochondria against endogenous ROS. The high reduc-
ing power of GSH also makes it a major contributor 
to the recycling of other oxidants that have become 
oxidized and could be a basis by which GSH helps con-
serve lipid-phase antioxidants like a-tocopherol (vi-
tamin E) (48,49). Mitochondria appear to be the most 
susceptible target in the GSH-depleted state. GSH pro-
tects mitochondria from lipid peroxidation by reducing 
phospholipid hydroperoxides and H2O2 (7).
 Catalase has been found in cardiac mitochon-
dria, albeit in minute amounts. It protects the organelle 
against intra- and extra-mitochondrial generated H2O2 
(7). Glutathione peroxidase (GPx) is ubiquitously ex-
pressed in mammalian tissues and is present in the 
mitochondrial matrix. Because of its quantity, it seems 
to be the predominant H2O2 detoxifying agent in the 
heart. Catalase or GPx coupled to glutathione reduct-
ase (GR) converts H2O2 to H2O  (Figure 2). There are vari-
ant isoforms of GPx. While some of the variants are in-
volved in detoxifying H2O2, other isoforms are involved 
in neutralizing lipid hydroperoxides (30) (Figure 2).
 Lastly, cytochrome c by its nature is a scaven-
ger. It is an effective electron acceptor and has been 
reported to act as a competent antioxidant system of 
mitochondria. It mediates and relays electron transfer 
between two sites that are critical in the generation of 
O2
•-, the site of electron transfer to complex IV and gen-
eration of O2
•- in complex III. Thus it is also a scavenger 
of O2
•- through its capacity to be reduced (15). 
 In cardiac I/R injury, and other acute diseases, 
loss of cytochrome c inhibits respiration and this can 
lead to increase electron leak (71); the outcome is more 
O2
•- production and more cell damage. Protecting car-
diolipin from I/R damage could help to preserve cyto-
chrome c and will not only facilitate the transfer of elec-
trons, but also contribute to the scavenging of ROS. In a 
recent study, Brooks et al. (9) showed that acute kidney 
damage was associated with increased mitochondrial 
fragmentation prior to cytochrome c release and ap-
optosis. Administration of exogenous cytochrome c to 
cytochrome c-depleted mitochondria reduced O2
•- ac-
cumulation and preserved organ function (84). Hence, 
maintaining the structural integrity of the IMM and cy-
tochrome c could represent a potentially useful strat-
egy for mitigating mitochondria-related cellular injury. 
 It is often noted that excess ROS and mCa2+ 
overload are the two major factors that are intertwined 
in the pathology of I/R injury. But how they are inter-
related or how they influence each other is a subject 
of intense debate. It suffices to note here that mCa2+ 
overload could lead to ROS production in part by mPTP 
opening and loss of GSH and NADH; these are all key 
factors involved in maintaining the redox balance in 
the GSH/GSSG system and thus provide efficient scav-
enging capacity (7) (Figure 2). Therefore, enhancing the 
endogenous levels of the GSH pool is a potentially vi-
able strategy to protect against mitochondria-related 
cellular injury. Thus pharmacologic and/or molecular 
approaches to preserve or minimize GSH depletion 
could be a useful option for protecting mitochondria. 
Alternatively, pharmacological or ischemic (pre- and 
post-conditioning) approaches could be made to insti-
gate protection mediated through a myriad of events 
that preserve mitochondrial redox state and protect 
the cell.  
    
Mitochondria and Targeted Therapeutic 
Approaches 
  Given the importance of mitochondrial events 
during the initial, critical phases of apoptosis, the de-
sign of mitochondriotropic drugs is considered a prom-
ising novel strategy in regulating apoptosis and cell 
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injury/death. Szewczyk and Wojtczak noted in a recent 
review (75) that medically applied drugs can be divided 
into two groups: 1) those that are specifically designed 
to affect mitochondrial function, and 2) those for which 
primary targets are other cellular locations and their 
interactions with mitochondria are secondary. Iden-
tification of the mitochondrion as a target of a thera-
peutic approach may assist in better understanding of 
mechanisms of action and provide new perspectives 
for treating diseases, including cardiovascular diseases. 
The subject of targeted approach to mitochondrial 
diseases has been discussed extensively in our recent 
review (15) and therefore will not be discussed further 
in this review. This review focuses mostly on pre- and 
post-conditioning strategies targeted to mitochondria. 
The premise here is that pre- and post-conditioning ef-
fects converge at the conceptual point of preserving 
the integrity of electron transfer to enhance mitochon-
drial bioenergetics and to minimize the deleterious ef-
fects associated with increased mitochondrial ROS and 
mCa2+ overload (15).     
Cardiac Mitochondria Protection against 
Ischemia and Reperfusion Injury: Implications 
for the Role of Pre- and Post-conditioning 
 There is ample support for the concept that 
mitochondrial function can be protected during glo-
bal ischemia as well as on reperfusion. This has been 
demonstrated in many studies, including inhibitors 
of sarcolemmal and mitochondrial Na+/H+ exchanger 
(NHE), hypothermia, and pre- and post-conditioning 
(ischemic or pharmacological) protocols. The protec-
tion is manifested largely as reduced mCa2+ uptake 
and O2
•- generation, improved redox state (NADH/FAD) 
and cardiac function, blunted mPTP opening, and a re-
duced infarction (15). 
 In a recent study (6) we reported that hyper-
kalemic, depolarizing cardioplegia was protective by 
a mitochondrial effect in addition to its effect on spar-
ing high-energy phosphates; in the same study we 
also showed that lidocaine, a hyperpolarizing agent, 
also protected hearts in part by a direct action on the 
mitochondria, a concept supported by other studies 
(19). We found that lidocaine blocked complex I as sug-
gested by an increased NADH without a change in FAD 
during lidocaine perfusion just before ischemia. This 
situation was analogous to what we observed with 
the complex I inhibitor amobarbital (3), which was also 
protective against cardiac I/R. 
 It has been a long-held belief that most cellular 
injury following I/R is initiated by events that happen 
on reperfusion. However, some of our recent studies 
and those by others have shown that events leading 
to I/R injury occur during ischemia and these events 
may extend to reperfusion to induce additional dam-
age (15). Restriction of oxidative metabolism during 
early reperfusion using a hypoxic reperfusate attenu-
ated mitochondrial and cardiac damage (20). In renal 
I/R-induced oxidative stress, repetitive hypoxic pre-
conditioning attenuated cell damage via a HIF-1a-de-
pendent signaling cascade that led to an increase in 
the anti-apoptotic Bcl-2 protein expression, inhibition 
of the cytosolic pro-apoptotic Bcl-2 protein expression, 
and inhibition of mitochondrial cytochrome c release 
(81). Initial reperfusion with mitochondrial-targeted 
peptides was reported to prevent myocardial stunning 
and to significantly improve contractility (73,74). There-
fore, there are a variety of strategies that can target mi-
tochondria in an attempt to interrupt the link between 
ischemic damage to mitochondria and mitochondria-
mediated cellular damage during reperfusion. It is be-
coming more evident that pre- and post-conditioning 
strategies and the sequelae of events provide protec-
tion in part by targeting mitochondria.  
 Pre-conditioning and post-conditioning have 
been demonstrated in numerous organs, including 
kidney, liver, brain and heart I/R (63,83). Some aspects 
of pre- and post-conditioning and how they modulate 
mitochondrial function have been discussed above. 
The earlier references to these two cardioprotective 
strategies are inevitable considering the broad aspect 
of the role of mitochondria in cytoprotection. Never-
theless, ischemic pre- and post-conditioning (IPC/IPoC) 
are cytoprotective measures that requires brief pulses 
of ischemic stress that confers resistance to a second, 
usually more severe stress, index ischemia or reper-
fusion, respectively. Pharmacological pre and post-con-
ditioning (PPC/PPoC) is a cardioprotective mechanism 
that mimics IPC/IPoC, in that a memory period of pro-
tection is created after removal of the stimulus or drug. 
Both pre- and post-conditioning mediate their protec-
tion in part by mitigating mitochondria-dependent cell 
damage. The protective effect is mediated by intrinsic 
pathway after the removal of a stimulus (brief ischemia 
or a drug) during the time before the onset of damag-
ing ischemia or on reperfusion. Thus the stimulus does 
not directly induce cytoprotection but rather some 
downstream signaling factors are evoked to provide 
a lasting protection (memory effect). Because post-
conditioning has the advantage that it can be applied 
after the ischemic insult has occurred (39,79,82), this is 
therapeutically a more favorable approach than is pre-
conditioning.
 IPC and PPC of the heart are known to de-
crease mitochondrial damage from subsequent in-
dex ischemia. IPC was identified as an endogenous 
cytoprotective phenomenon, whereas PPC has the 
advantage of not requiring brief episodes of ischemia 
to elicit cellular protection (15). Of interesting clinical 
relevance, patients who have experienced angina be-
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fore myocardial infarction repeatedly exhibit an im-
proved post-infarction prognosis compared with those 
without antecedent angina. Pre-conditioning-induced 
ischemic tolerance has been evaluated in humans dur-
ing angioplasty and before initiation of cardiac bypass 
(11). 
 Because pre-conditioning must be applied be-
fore an ischemic event to be protective, this limits its 
usefulness clinically since ischemia and tissue injury 
are often not predictable and these procedures are 
seldom instituted early enough to minimize infarction 
(77). Post-conditioning (ischemic or pharmacological), 
however, requires a very brief period of secondary I/R 
or brief exposure to drugs with subsequent washout, 
during the early reperfusion period. The period of the 
post-conditioning protection, which must be imple-
mented immediately upon reperfusion, is significant 
because it marks the critical time at which maximal 
cell damage might be reduced (15). This period coin-
cides with surges in ROS production, mCa2+ overload, 
and mPTP opening (79,82), or at least initiation of ap-
optotic mechanisms. Post-conditioning may also pro-
tect against I/R injury at least in part by maintaining an 
acidic pH during reperfusion, which may inhibit mPTP 
opening. Delayed opening of the mPTP has also been 
implicated in PPC afforded cardioprotection. Treat-
ment with atractyloside, an mPTP opener, abolished 
the infarct-reducing effects of nitric oxide-induced 
preconditioning (27). Interventions aimed at limiting 
cell injury during reperfusion i.e. post-conditioning, 
whether ischemic or pharmacologic, may also be me-
diated through similar mechanisms. Indeed pre- and 
post-conditioning have been shown to evoke similar 
cytoprotective mechanisms/pathways that initiate or 
end at the mitochondria (15). 
 The cellular and mitochondrial protection elic-
ited from both IPC and PPC involve a coordinated in-
terplay of multiple trigger and effector mechanisms, 
mostly phosphorylation and dephosphorylation of 
select enzymes. There is much circumstantial evidence 
that mitochondria-derived ROS play an important role 
in initiating IPC and PPC (15), which are effected by 
intracellular protein kinase cascades, especially PKCe 
(36), tyrosine kinases, and MAPK (83). These signaling 
pathways have been discussed extensively in a review 
by Yellon and Downey (83), and will not be discussed 
here. Nonetheless, the key effector signaling pathways 
for both cytoprotective strategies appear to result in 
the modulation of mitochondrial oxidative metabolism 
before prolonged ischemia, or to prevent mPTP open-
ing on reperfusion. 
 Early experiments showed that IPC in the heart 
was abrogated when the pre-conditioning pulses were 
preceded by 5-hydroxy decanoate (5-HD) and not by 
HMR1098, the selective antagonist for the sarcolemmal 
KATP channel. This suggested that the mKATP channel is a 
mediator of IPC by modulating mitochondrial bioener-
getics. However, prolonged opening of the purported 
mitochondrial channel during ischemia did not confer 
protection. It is presently disputed whether 5-HD or 
glibenclamide, applied after preconditioning just be-
fore index ischemia, abrogates protection. But, several 
studies have shown that the application of 5-HD after 
the preconditioning protocol abrogated protection 
(54).   
 Conversely, administration of diazoxide, the pu-
tative mKATP agonist conferred protection, possibly by 
inducing a mild depolarization of the DYm. This would 
dissipate the energy that is normally used by the F1F0 
ATPase to produce ATP; hence, mKATP channel opening 
would result in mild uncoupling of mitochondrial ATP 
production (54) to protect the organ. By depolarizing 
mitochondria, diazoxide may reduce mCa2+ uptake and 
decrease pathological ROS generation, while reducing 
permeabilization of OMM due to translocation of proa-
poptotic proteins from the cytosol to the mitochondria 
or induction of mPTP opening (54). Interestingly, the 
initial mild uncoupling induced directly by diazoxide 
may be due to its attenuation of complex II (34); this 
may lead to a small release of mitochondrial ROS that 
many believe is the primary initial signaling event that 
lead to the activation of down-stream end-effectors. 
Most studies have demonstrated that ROS scavenging 
prevents IPC, thus implicating the initial requirement 
for ROS in IPC and PPC. For example the mitochon-
drial O2
•- scavenger N-mercaptopropionyl glycine was 
shown to block the protective effects of diazoxide (57). 
 Much of the work on PPC has centered on the 
volatile anesthetics and their potential for organ pro-
tection during the stress of surgery. The volatile anes-
thetics have long been known to provide overall pro-
tection against the effects of cardiac I/R because of 
their mild coronary vasodilatory and their negative ino-
tropic effects. These effects correspondingly decrease 
metabolic demand and increase O2 supply, while hav-
ing a direct suppressive effect on myocardial Ca2+ entry 
through L-type Ca2+ channels (14). In contrast, protec-
tion against cell injury after only a brief exposure to a 
volatile anesthetic, anesthetic pre-conditioning (APC), 
provides protection against I/R injury similar to IPC and 
other drugs, invoking similar signaling pathways and 
end effectors. As in IPC, scavengers of ROS abrogate 
APC, suggesting an effect of anesthetic agents to also 
induce ROS formation (15). The mechanism by which 
these drugs induce ROS formation is unclear. However, 
volatile anesthetics directly inhibit mitochondrial ETC 
complex activity (especially complex I) and thus alter 
mitochondrial bioenergetics; this strongly implicates 
the mitochondrion as the target for these effects.  Fur-
thermore, the release of small amount of ROS during 
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APC causes a dramatic decrease in mitochondrial ROS 
formation during I/R and this might underlie the im-
proved post-ischemic organ function and reduction in 
infarct size (15).    
 APC holds an obvious advantage over IPC from 
the practical standpoint that volatile anesthetics can 
be easily and safely administered. Novalija et al. (52) 
reported that APC was manifested by improved car-
diac function and decreased infarct size compared to 
controls. When a mixture of ROS scavengers, i.e. SOD, 
catalase and GSH, or the NOS inhibitor L-NAME, were 
given during the sevoflurane pretreatment phase, pro-
tection was abrogated in all respects.  Kevin et al. (38) 
similarly pre-conditioned guinea pig isolated hearts 
with sevoflurane and MnTBAP abrogated the APC. Sed-
lic et al. (67) reported recently that isoflurane, like DNP, 
protected cardiomyocytes in part via a mild decrease in 
Ym, which attenuates pathologic ROS production under 
stress and delays mPTP opening and increases cell sur-
vival. These studies all strongly support the probabil-
ity that modulation of mitochondrial bioenergetics by 
preconditioning induces cytoprotective mechanisms 
manifested at the level of the mitochondrion (15). 
 Like the putative mKATP channel, we have 
shown that the putative mCa2+-dependent K+ channel 
(mKCa) may also play a role in modulating mitochon-
drial bioenergetics and provide pre-conditioning pro-
tection against cardiac I/R injury (15). We reported that 
pre-treatment with NS1619, the KCa channel agonist 
protected the heart from ischemic injury (70). NS1619, 
given before ischemia, preserved the mitochondrial 
redox state (increased NADH and decreased FAD) and 
improved cardiac function. Paxilline, an NS1619 an-
tagonist, and MnTBAP, both abolished preservation of 
mitochondrial bioenergetics and cardiac protection 
by NS1619 (70). These findings attest to the role mito-
chondria play in the protection and damage of the cell 
during I/R stress. 
 It is widely acknowledged that at the cellu-
lar level, reperfusion activates a number of processes 
that increase cell injury. The surge in ROS during late 
ischemia coupled with the rapid increase in O2 on early 
reperfusion contributes to events that lead to a vicious 
cycle of more ROS/RNS production and further mito-
chondrial damage. Reperfusion also contributes to an 
increase in mCa2+ overload, which along with increases 
in ROS/RNS and a relatively less acidic intracellular pH 
may lead mPTP opening. This results in mitochondrial 
swelling and uncoupling of the ETC and collapse of the 
DYm, cytochrome c release, decline in ATP production, 
and cell death. 
 Like IPC/PPC, PoC, ischemic (IPoC) or pharma-
cological (PPoC), have been shown to be protective 
in numerous animal models and recent evidence sug-
gests that it may work in humans (51). Administration 
of a wide variety of drugs (32,47,55,56), immediately on 
reperfusion has been shown to provide protection that 
is as effective as IPC. Many of the signaling pathways 
instigated by pre-conditioning are also implicated in 
PoC (55). Post-conditioning protection is also medi-
ated in part by targeting the mitochondrion, either as 
an initial triggering phase of the process, or as an end-
effector, or both. For example, in a recent study, Ge et 
al. reported that the cardioprotection by anesthetic 
post-conditioning (APoC) appears to be mediated via 
the mPTP (29). In this study Ge et al. (29) showed that 
isoflurane post-conditioning failed to alter infarct size, 
cardiac function, or the amount of Ca2+ necessary to ac-
tivate the mPTP from the eNOS-/- hearts compared with 
the wild type. It was concluded that APoC protected 
mouse hearts from reperfusion injury by preventing 
mPTP opening in an e-NOS dependent manner, and 
that NO• may be acting as both trigger and a mediator 
of APoC protection (29). 
 To date, it is unresolved if similar signaling 
pathways in pre-conditioning protection are involved 
in mediating post-conditioning protection. However, 
from recent evidence it appears that similar signaling 
mediators, which are activated at the time of reper-
fusion PoC (55), modulate cytoprotection. In addition, 
Feng et al. (25) showed that both IPC and PPoC might 
provide protection by reversing ischemia-induced ANT 
dephosphorylation and thereby improve ATP produc-
tion. In a related study, Cheng et al. (21) reported that 
dephosphorylation of ANT results in an increase in ANT 
activity following incorporation of the purified protein 
in a lipid bilayer model. Thus, a dephosphorylated ANT 
can potentially lead to the detrimental consequence of 
mPTP opening (21) with subsequent cell injury. Unlike 
IPC, the major limitation with PoC is that it is unlikely to 
evoke pro-survival signaling pathways rapidly enough 
to avert cellular injury early on reperfusion. Therefore 
other faster remedies independent of signaling pro-
teins could be considered as more effective during the 
initial phase of reperfusion.
 Indeed, in a recent study, Pravdic et al. (60) re-
ported that APoC better preserved matrix acidic pH dur-
ing reperfusion than the control group, which delayed 
mPTP opening and contributed to the preservation of 
mitochondria and better cytoprotection. Similarly, we 
have observed that post-ischemic hypothermic treat-
ment also protects against I/R damage by protecting 
mitochondria. We also observed that addition of ROS 
scavengers during hypothermic post-ischemic per-
fusion provided additional protection of mitochondria 
and improved global cardiac function (unpublished 
data). These novel observations imply that cytopro-
tective strategies can be elicited by directly targeting 
mitochondria independent of activation of signaling 
cascades that require time to be activated. This strat-
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egy could herald an alternative approach to mitigate 
reperfusion-mediated injury.
 In another post-ischemic study, we observed 
that brief perfusion with NS 1619 (within 10 min reper-
fusion) after 30 min of global ischemia also preserved 
mitochondria, improved cardiac function, and reduced 
infarction when compared to untreated hearts. Inter-
estingly, we also observed that brief perfusion of paxil-
line on reperfusion worsened mitochondrial bioener-
getics and further impaired functional recovery when 
compared to the untreated (control) hearts (78). These 
novel results suggested that the putative mKCa channels 
may be opened during early reperfusion and intrinsi-
cally contribute to reducing mitochondrial damage 
and concomitant cellular injury. Therefore, effective 
therapeutic targeting of these mitochondrial channels 
during reperfusion could represent additional valu-
able approach that could have clinical utility during I/R 
procedures. In this case, mKCa channel agonists could 
be used as adjuvant therapy with other mitochondri-
al targeted approaches to provide further protection 
against oxidative/nitrosative damage.  
 It is noteworthy that conventional pre- and 
post-conditioning provide minimal cardioprotection in 
the aged rat (1,76) and in human hearts (50). The lack of 
conventional cardioprotection in the aged heart could 
be attributed to the decline in mitochondrial func-
tion and possible imbalances in ROS generation and 
scavenging, with greater net ROS emission. Indeed, 
in the aged heart, ischemic damage to mitochondria 
is superimposed upon aging-induced defects in mito-
chondrial oxidative metabolism (43,44,46) as a conse-
quence of decreases in complex I and IV activities (23) 
with concomitant increase in ROS emission. The aged 
heart generally sustains increased damage during I/R 
(8,26,42). Older patients with ischemic heart disease 
generally have impaired recovery of myocardial func-
tion after cardiac surgery or other cardiac interventions 
when compared to younger patients (61). 
 Insofar as the aged heart could not be pre- or 
post-conditioned, other mitochondria-targeted ap-
proaches have shown potential for cardioprotection. 
For example, nutrition fortified with acetylcarnitine has 
been shown to restore cardiolipin and mitochondrial 
function in aged hearts (12,45). It has been reported 
that blocking complex I before ischemia, unlike pre-
conditioning, protects the aging heart from I/R injury 
and protects mitochondria (45). These observations 
provide strong empirical evidence for the association 
of aging-related defects in mitochondrial metabolism 
to the enhanced damage in old hearts. This also high-
lights the importance of considering other approaches 
to modulate mitochondrial oxidative metabolism to 
protect the aged heart (15).   
 
Conclusion 
 Most of this review has concentrated on de-
fined approaches, i.e. pre- and post-conditioning and 
some direct approaches, to alter mitochondrial func-
tion in treating or preventing I/R injury.  Clearly, the 
efficacies of these approaches remain to be resolved. 
Furthermore, targeting mitochondria for specific ther-
apeutic purposes could pose a dilemma of how to 
protect, while at the same time, preserve normal cel-
lular function. Different cells and tissues have distinct 
sensitivities and responses to mitochondrial dysfunc-
tion (15). Appreciation of these differences will be im-
portant when considering mitochondrial therapeu-
tic strategies in a more integrated setting than in an 
isolated cells, isolated mitochondria or in an isolated 
heart model. Nonetheless, most current efforts are fo-
cused on preventing mitochondrial oxidative damage 
that arises from deleterious conditions. These include 
decreasing mPTP opening, decreasing DYm to reduce 
O2
•- production, and limiting mCa2+ overload. Pre- and 
post-conditioning have both minimized mitochondrial 
damage and attenuated cell injury by targeting the 
above mitochondrial variables, directly or indirectly. 
However, proper design and refinement of current 
mitochondriotropic drugs may seem to be the most 
promising approach to prevent or treat mitochondrial 
dysfunction like cardiac I/R injury, as we have stressed 
in this review. As noted previously (15), much work is re-
quired to develop and improve mitochondria-directed 
strategies that would lead to better protection of the 
heart against I/R injury. Any such targeted approach 
should have the potential for clinical translation.   
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